Oxidative stress in blood in cases of untreated refractory anaemia

Journal of B.U.ON.

Volumn 10, Issue 2, 2005, Pages 257-260

  Tzvetkov, Nikolai ^a   Bochev, P ^a   Alexandrova, M ^a  

^a MEDICAL UNIVERSITY PLEVEN   (Bulgaria)

Author keywords

Antioxidants; Chemiluminescence; Lipid peroxidation; Myelodysplastic syndromes; Oxygen free radicals; Refractory anaemia

Indexed keywords

ANTIOXIDANT; CATALASE; FREE RADICAL; MALONALDEHYDE; OXYGEN RADICAL; SUPEROXIDE DISMUTASE; THIOL DERIVATIVE;

ADULT; AGED; ARTICLE; BIOSYNTHESIS; BLOOD ANALYSIS; CELL ACTIVITY; CELLULAR DISTRIBUTION; CHEMOLUMINESCENCE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LOCALIZATION; ERYTHROCYTE; ERYTHROCYTE MEMBRANE; FEMALE; HUMAN; IRON OVERLOAD; LEUKOCYTE ACTIVATION; LIPID PEROXIDATION; MALE; NEUTROPHIL; OXIDATIVE STRESS; PATHOGENESIS; REFRACTORY ANEMIA;

EID: 24944538668     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Shimazaki K, Ohshima K, Suzumiya J, Kawasaki C, Kikuchi M. Evaluation of apoptosis as a prognostic factor in myelodysplastic syndromes. Br J Haematol 2000; 110: 584-590.
2. Parker J, Mufti G. The role of apoptosis in the pathogenesis of the myelodysplastic syndromes. Int J Hematol 2001; 73: 416-428.
3. Claessens Y, Fontenay-Roupie M. Physiopathology of myelodysplastic syndromes. Pathol Biol 2002; 50: 261-267.
4. Emura I. High incidence of apoptosis in peripheral blood of myelodysplastic syndrome patients determined by Papanicolaou-stained preparations. Lab Hematol 2003; 9: 42-46.
5. Farquhar M, Bowen D. Oxidative stress and the myelodysplastic syndromes. Int J Hematol 2003; 77: 342-350.
6. Peddie C, Wolf R, McLellan L, Collins A, Bowen D. Oxidative DNA damage in CD34+ myelodysplastic cells is associated with intracellular redox changes and elevated plasma tumor necrosis factor -α concentration. Br J Haematol 1997; 90: 675-631.
7. Tauro S, Hepburn M, Bowen D, Pippard M. Assessment of stromal function, and its potential contribution to deregulation of hematopoiesis in the myelodysplastic syndromes. Haematologica 2001; 86: 1038-1045.
8. Fracchiolla N, Catena F, Novembrino C, Ippolito S, Maisonneuve P, Cortelezzi A. Possible association between oxygen metabolites and karyotypic abnormalities in myelodysplastic syndromes. Haematologica 2003; 88: 294-297.
9. Invernizzi R, Travaglino E, Gobbi P, Malabarba L, Ramajoli I, Ascari E. Clinical and biological effects of treatment with amifostine in myelodysplastic syndromes. Br J Haematol 2002; 118: 246-250.
10. Levina AA, Andreeva AP, Tsvetaeva NV, Tsibulskaya MM, Minaeva LM, Tokarev YuN. Antioxidant activity of serum and erythrocytes in patients with refractory anemia. Hematol Transfusiol 1991; 36: 11-14.
11. Jensen PD, Jensen IM, Ellegaard J. Desferrioxamine treatment reduces blood transfusion requirements in patients with myelodysplastic syndrome. Br J Haematol 1992; 80: 121-124.
12. Cortelezzi A, Cattaneo C, Cristiani S et al. Non-transferrin-bound iron in myelodysplastic syndromes as a marker of ineffective erythropoiesis. Hematol J 2000; 1: 153-158.
13. Gazzola M, Barosi G, Gobbi PG, Invernizzi R, Riccardi A, Ascari E. Natural history of idiopathic refractory sideroblastic anemia. Blood 1988; 71: 305-312.
14. Asakawa T, Matsushita S. Thiobarbituric acid test for detecting lipid peroxides. Lipids 1980; 14: 401-406.
15. Maral J, Puget K, Michelson A. Comparative studies of SOD, catalase and glutathione peroxidase in erythrocytes of different animals. Biochem Biophys Res Common 1977; 77: 1525-1535.
16. Cohen G, Dembiec D, Marcus J. Measurement of catalase activity in tissue extracts. Ann Biochem 1970; 34; 30-38.
17. Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys 1959; 82: 70-77.
18. Bochev P, Bechev B, Magrisso M. Six-sample multiplexing computerized analyser for integral and spectral luminescence measurements. Ann Chim Acta 1992; 256: 29-32.
19. Ristola M, Repo H. Whole blood luminol-enhanced chemiluminescence: Statistical analysis of the responses of different subjects. J Biolum Chemilum 1990; 5: 155-160.
20. Cortelezzi A, Francchiolla N, Bamonti-Catena F et al. Hyperhomocysteinemia in myelodysplastic syndromes: specific association with autoimmunity and cardiovascular disease. Leuk Lymphoma 2001; 41: 147-150.
21. Omata F, Nakazawa H, Nakano M, Arimori S. Erythrocyte superoxide dismutase in various hematological diseases. Tocai J Exp Clin Med 1990; 15: 99-106.
22. Boogaerts MA, Nelissen V, Roelant C, Goossens W. Blood neutrophil function in primary myelodysplastic syndromes. Br J Haematol 1983; 55: 217-227.
23. Boogaerts MA, Meeus P, Verhoef G, Malbrain S, Van Hove L, Verwilghen RL. Differential effects of IL-3, GM-CSF and G-CSF on preleukemic granulocytes. Blood 1988; 72 (Suppl): 110-116.
24. Verhoef G, Boogaerts M. In vivo administration of granulocyte-macrophage colony stimulating factor enhances neutrophil function in patients with myelodysplastic syndromes. Br J Haemotol 1991; 79: 177-184.
25. Zwierzina H, Holzinger I, Gaggl S et al. Recombinant human interleukin-8 restores function in neutrophils from patients with myelodysplastic syndromes without stimulating myeloid progenitor cells. Scand J Immunol 1993; 37: 322-328.
26. Britigan BE, Edeker BL. Pseudomonas and neutrophil products modify transferrin and lactoferrin to create conditions that favor hydroxyl radical formation. J Clin Invest 1991; 88: 1092-1102.
27. Rosen GM, Pou S, Ramos LL, Cohen MS, Britigan BE. Free radicals and phagocytic cells. FASEB J 1995; 9: 200-209.
28. Khwaja A, Carver J, Linch D. Interactions of granulocyte-macrophage colony-stimulating factor (CSF), granulocyte CSF, and tumor necrosis factor alpha in the priming of neutrophil respiratory burst. Blood 1992; 79: 745-753.
29. Jensen PD, Heickendorff L, Pedersen B et al. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol 1996; 94: 288-299.